CoMind Raises Over $100 Million to Pioneer Non-Invasive Brain-Monitoring Technology
London-based neurotechnology startup CoMind has successfully secured over $100 million in total funding, with its latest round led by venture firm Plural and participation from returning backers including Angelini Ventures, LocalGlobe, Octopus Ventures, Crane Venture Partners, BACKED VC and Entrepreneurs First (EF).
CoMind’s core innovation is a non-invasive brain-monitoring device that uses optical and photonic sensing to measure key neurological parameters such as cerebral blood flow, intracranial pressure and autoregulation without needing invasive surgical procedures. The company’s technology is designed for use in critical-care settings, surgery and traumatic brain-injury treatment, offering a potentially transformative alternative to traditional intravascular sensors.
With this funding, CoMind is poised to accelerate the development of its flagship device, expand clinical trials (including a third U.S. trial), work toward regulatory clearance in the U.S. and scale manufacturing partnerships. The support from a top-tier investor syndicate underscores confidence not only in the technology but also in the growing demand for non-invasive neuromonitoring tools.
The raise comes amid increasing attention on brain health monitoring: as hospitals and healthcare systems seek less-invasive, continuous monitoring solutions, CoMind’s approach stands out for its ambition to bring bedside monitoring of the brain closer to what’s standard for other organs like the heart or lungs. Backers such as Plural and Angelini Ventures emphasise the company’s position at the intersection of high-impact medtech, AI-driven analytics and hardware innovation.
Challenges still lie ahead for CoMind as it works toward commercial deployment. The company must demonstrate regulatory safety and efficacy, build manufacturing scale, secure reimbursement pathways in healthcare systems, and sustain operations through the complex sales cycles typical of medical-device startups. However, with over $100 million in funding and a strong investor base aligned to its mission, CoMind is now well-positioned to lead a significant shift in how brain monitoring is approached in clinical care.
The latest funding round and investor backing mark a major milestone for CoMind. With strategic support from Plural and a cohort of seasoned venture investors, the company is moving rapidly toward delivering its novel brain-monitoring technology into hospitals globally — a step that could reshape critical-care neurology and patient monitoring for years to come.
